18223 Long-term proactive management of psoriasis vulgaris with fixed-dose combination of 0.005% calcipotriene and 0.064% betamethasone dipropionate foam: Results of a phase III randomized controlled trial

Abstract

Patients received once-daily Cal/BD during the four-week open-label phase (NCT02899962). Patients achieving success (physician’s global assessment of disease severity [PGA] score ‘clear’/‘almost clear’ with ≥2-grade improvement from baseline) were randomized 1:1 in a double-blind fashion to twice-weekly Cal/BD or vehicle for 52 weeks. Eligibility criteria: ≥18 years; truncal and/or limb psoriasis, involving 2%-30% of body surface area; PGA ≥ ‘mild’ and modified psoriasis area and severity index score ≥2 at visit 1.